Nexalin Technology : Investor Presentation March 2026
NXL
Published on 04/20/2026 at 03:21 pm EDT
HARNESSING THE POWER OF ADVANCED FREQUENCY
NEUROSTIMULATION TO IMPROVE MENTAL HEALTH
INVESTOR PRESENTATION | MARCH 2026 NASDAQ: NXL
Mental Health is a Global Epidemic
A Market full of Drugs, a Mind Full of Problems
Anxiety2
360M*
Insomnia1
850M*
Alzheimer's
and Dementia2
60M*
Depression2
330M*
TBI/PTSD (Military)2,3
350M*
* Number of Patients
INVESTOR PRESENTATION | MARCH 2026 3
Drugs & Therapy Are Big Business
Market Opportunity: $60 Billion and Growing
DRUG TREATMENTS THAT DON'T TREAT:
Insomnia4
Anxiety5
Alzheimer's
and Dementia6
Depression6
TBI/PTSD
(Military) 7
PATIENT POPULATION
850M
360M
60M
330M
350M
MARKET SIZE ($)
$ 5 B
$ 12 B
$ 5 B
$ 22 B
$ 16 B
Low Efficacy
Dangerous Side Effects
Addiction
Lifetime of medication
Stigma
70%
Prefer
drug-free
alternative8
INVESTOR PRESENTATION | MARCH 2026 4
More Treatments that Don't Treat
Current non-invasive neurostimulation technologies are marketed as alternatives to drugs but are limited by safety and efficacy:
SAFETY
EFFICACY
Treatment response is limited by patient's threshold of discomfort
Limited power = limited efficacy (1-1.5 mA)
Nexalin: 15mA
Unregulated usage for some
(no physician oversight)
Treatment response is less than or equal to medication (<50%)9,10
THESE TECHNOLOGIES FAIL TO MEET PATIENT NEEDS.
INVESTOR PRESENTATION | MARCH 2026 5
The Future of Mental Health Treatment is Here
Nexalin is replacing all current neurostimulator technologies with its new Deep Intracranial Frequency Stimulation (DIFS®).
Undetectable to
the human body
No patient discomfort or side effects
15x more powerful than current neurostimulators*
Increased power allows
for deeper penetration
Deeper penetration, better response
Treatment response based on clinical evidence
*Compared to 1mA
INVESTOR PRESENTATION | MARCH 2026 6
Deep Intracranial Frequency Stimulation (DIFS®)
Our DIFS device mirrors the brain's natural energy rhythms to effectively
reset and retrain networks associated with trauma.
Nexalin's undetectable proprietary waveform is unique in shape, amplitude, and frequency that mirrors the natural rhythms of the brain
Greater power = deeper penetration = greater response
Deeper penetration in mid-brain structures without side effects or patient discomfort
DIFS influences the production of neurotransmitters like serotonin and dopamine
Low risk (no side effects) with high efficacy
INVESTOR PRESENTATION | MARCH 2026 7
Nexalin's Frequency Stimulation is not a Hypothesis
Summary of clinical trials:
33 clinical trials
13 of these are International peer-reviewed clinical trials
7 of these validated by neuroimaging (PET Scan, fMRI, MEG)
Publications:
12 publications (available on
the Nexalin website)
3 recent articles published on the treatment of Alzheimer's Dementia (AD)
TBI / PTSD clinical trial completed at UCSD with positive results
developing new clinical strategies in collaboration with the FDA Q-submission application.
INVESTOR PRESENTATION | MARCH 2026 8
PRODUCT AND STRATEGY
INVESTOR PRESENTATION | MARCH 2026 9
From Proven Foundation to Next-Generation Neurostimulation
NEXALIN GEN 1* ✓ Waveform Technology
In clinic solution
1-2 milliamp (mA), 77.5Hz frequency waveform for treatment without any discomfort or side effects
Originally FDA cleared for anxiety, depression, and insomnia
Cost Effective
Lower patient and provider costs
*Nexalin no longer markets or distributes this Gen-1 clinical solution
INVESTOR PRESENTATION | MARCH 2026 10
OVERALL GROWTH
STRATEGY GEN 2 - SYNC
Clinical Device
More advanced, powerful
GEN 3 - HALO
Remote Device
Enhanced access through virtual clinic
Three regulatory pathways leading to commercialization
Mood disorders - Anxiety,
GEN 1 - FDA
Anxiety, Depression, Insomnia
technology
Depression, Insomnia
Alzheimer's and Dementia
TBI/PTSD (military)
INVESTOR PRESENTATION | MARCH 2026 11
Nexalin's Advanced Gen 2 - SYNC Technology
Allows for deeper brain penetration and greater efficacy (clinically based)
NEXALIN GEN 2 - SYNC ✓ Proprietary Waveform
In clinic solution
15 milliamp (mA) waveform for deeper penetration.
Increased Efficacy Proven effectiveness in mental health disorders
Regulatory Confidence Regulatory approval in Asia (China), Brazil, Middle East, and Israel
FDA Clinical Strategy Pilot and pivotal trials beginning in USA 2025
INVESTOR PRESENTATION | MARCH 2026 12
BRINGING ADVANCED, NON-INVASIVE TREATMENT INTO THE HOME
13
Nexalin's Gen 3 - HALO Device
Allows patients to receive advanced neurostimulation treatment in their home with clinical supervision
NEXALIN GEN 3 - HALO ✓ Same Increased Efficacy
In home virtual clinic solution
as Gen 2 - SYNC
Convenient At Home Treatment through App and Virtual Clinic
FDA Q-submissions filed, collaborating with FDA on clinical design strategies
FDA application expected 2026
INVESTOR PRESENTATION | MARCH 2026 14
Patient self-administers treatment 5x per week for 4-6 weeks at home
1
Physician Monitors Patient Compliance and Safety Through the Virtual Clinic:
2
Provider prescribes the Nexalin HALO through a digital ecosystem known as a virtual clinic
3
Provider uses software to access headset, assign protocol, and monitor patient compliance
Provider and patient collaborate through app server and physician portal
INVESTOR PRESENTATION | MARCH 2026 15
IN SUMMARY:
Nexalin Portfolio Poised For Rapid Commercial Growth
INSOMNIA
DEPRESSION
ANXIETY
Alzheimer's and
DEMENTIA
TBI/PTSD (Military)
2025 2026 2027
GEN 2 SYNC
GEN 3 HALO
N/A
In Market (JV)
China, Brazil, Oman
Pilot and Pivotal FDA Clinical Trials in USA
Pilot and Pivotal Clinical Trials Internationally
FDA De Novo Clinical Trial Strategy USA
I N T E R N A T I O N A L
U S A
I N T E R N A T I O N A L
U S A
INVESTOR PRESENTATION | MARCH 2026 16
MARKET AND BUSINESS MODEL
INVESTOR PRESENTATION | MARCH 2026 17
Go-to-Market Strategy
Three Pathways
Mood:
Anxiety | Depression | Insomnia
Military: TBI | PTSD
AD: Alzheimer's Disease
Product Strategy
Gen 2 - SYNC: Sell device to clinician/ clinic; single-use electrode drives long-term revenue
Gen 3 - HALO: Sell device + monthly subscription drives long-term revenue
Customers
Clinicians and patients
(all pathways)
Delivery Model
Digital technology + digital treatment + digital distribution
All pathways connected
Patient Acquisition: Digital media, paid media, targeted consumer strategies, physician community referral
INVESTOR PRESENTATION | MARCH 2026 18
National and International Regulatory Strategy
Nexalin is currently collaborating with FDA on clinical study design and
strategy for De Novo clinical treatment application
National: FDA applications (treatment, breakthrough) filing strategy:
First tranche - Insomnia, Alzheimer's & Dementia
Second tranche - TBI/PTSD, Depression
Third tranche (in development) -
Anxiety, Addiction, Chronic Pain
International
Current clearance with NMPA in Asia (China): Depression, Insomnia
Current ANVISA approval in South America (Brazil): Anxiety, Depression, Insomnia
Current clearance with Ministry of Health in Middle East (Oman): Anxiety, Depression, Insomnia
Current clearance with Ministry of Health in Israel: Anxiety, Depression, Insomnia
INVESTOR PRESENTATION | MARCH 2026 19
Clinical Data / Sales Support - Mood Disorders
Insomnia / Depression: 75-90% of Patients Improve
100%
77%
Active Gr
oup
100%
94%
Active Gr
oup
50%
53%
Sham Group
50%
54%
Sham Group
20% 17%
0%
20% 18%
0%
NEXALIN TECHNOLOGY CLINICS
DEPRESSION
INSOMNIA
Diagnosed Average Improvement
74%
77%
INVESTOR PRESENTATION | MARCH 2026 20
Disclaimer
Nexalin Technology Inc. published this content on April 20, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 20, 2026 at 19:20 UTC.